David Fabrizio - Researcher Profile | RDL Research Database

Publications

2 shown

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle , Marwan Fakih , Juanita Lopez +18 more

2020 The Lancet Oncology 2300 citations

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis , Michael E. Goldberg , Danielle Greenawalt +66 more

Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups o...

2018 Cancer Discovery 1505 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 3,805
Institution: Foundation Medicine (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-8088-9476

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.